相关实验视频
Updated: Jun 25, 2026

10:03
A Zebrafish Model of Diabetes Mellitus and Metabolic Memory
Published on: February 28, 2013
在2型糖尿病中争取早期有效的血糖和体重管理:叙述性综述
Alice Y Y Cheng1, Robert J Heine2, Stefano Del Prato3
1Department of Medicine, University of Toronto, Toronto, Ontario, Canada.
Diabetes, obesity & metabolism
|January 28, 2025
概括
在2型糖尿病 (T2D) 中实现早期的血糖控制和体重管理提供了长期的好处. 解决过度脂肪是有效的T2D护理的关键,改善结果,并可能创造持久的遗留效应.
科学领域:
- 内分泌学 在内分泌学.
- 代谢疾病 代谢疾病
- 糖尿病管理 糖尿病管理
背景情况:
- 许多2型糖尿病 (T2D) 患者无法达到代谢治疗的目标.
- 传统的T2D治疗带来了低血糖和体重增加等风险,导致了保守的方法.
- 以前的模式未能充分解决过度脂肪,这是T2D的关键因素.
研究的目的:
- 审查关于早期血糖控制对T2D的长期益处的证据.
- 检查在T2D护理中管理体重的影响.
- 讨论全面T2D管理的未来方向.
主要方法:
- 对现有证据的文献审查.
- 对T2D中血糖控制和体重管理研究的分析.
- 综合与长期T2D结果相关的发现.
主要成果:
- 早期的密集血糖控制可能会产生具有持久益处的"遗留效应".
- 有效管理多余脂肪是T2D护理的组成部分.
- 优化治疗策略可以改善T2D的代谢结果.
结论:
- 早期和积极的T2D管理,包括体重控制是必不可少的.
- 需要向解决T2D核心异常,如肥胖症的模式转变.
- 进一步的研究应该集中在优化长期T2D管理策略上.
相关概念视频
Carbohydrate Metabolism
10.8K
Carbohydrates are polymers composed of molecules containing atoms of carbon, hydrogen and oxygen. One gram of carbohydrate can provide four kilo-calories of energy, which makes it the most efficient instant energy source.
Starch accounts for approximately 60% of the carbohydrates consumed by humans. Since amylase enzymes cannot function in the stomach's acidic environment, starch can only be digested in the mouth and small intestine. Simple sugars are found naturally in milk and fruits in...
Starch accounts for approximately 60% of the carbohydrates consumed by humans. Since amylase enzymes cannot function in the stomach's acidic environment, starch can only be digested in the mouth and small intestine. Simple sugars are found naturally in milk and fruits in...
10.8K
Diabetes Mellitus: Type 2 and Gestational
2.2K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.2K
Diabetes: Management and Pharmacotherapy
233
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
233
Oral Hypoglycemic Agents: Biguanides and Glitazones
164
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
164
Oral Hypoglycemic Agents: Glinides
136
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
136
Glucagon-like Receptor Agonists
294
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
294

